

PAG cooperation 2024	<i>Migræne forum samarbejdsaftale</i>
<i>Name of Organisation</i>	<i>Lundbeck Pharma A/S</i>
<i>Name of activity</i>	<i>Migraine forum</i>
<i>Name of the Parties entered into agreement</i>	<i>Danmarks patientforening for hovedpineramte, Migræne og Hovedpine foreningen, Migræne Danmark, this agreement is a joint agreement between the patient organisations and Abbvie, Novartis, Pfizer, Teva and Lundbeck A/S</i>
<i>Purpose</i>	<i>Lundbeck pharma A/S have engaged in this collaboratin to discuss and share knowledge, experiences and ideas with the aim of secure disease awareness of the burden of disease and to foster the possibility of improving the conditions for patients suffering from migraine</i>
<i>Roles of the parties</i>	<i>The cooperation (discussions)consists in 2024 of one or more meetings where the Parties meet for approximately 2-3 hours (physically and/or online. Possibility of online participation in all meetings). The meetings are held adhoc according to mutual agreement and needs. Invitation and preliminary agenda are sent to meeting participants approximately 14 days before the meeting. Participants and brief minutes of the meetings are sent to the participants after the meeting</i>
<i>Timeframe</i>	<i>5/2 - 31/12 24</i>
<i>Amount of funding and what it is used for</i>	<i>None</i>
<i>Scope and content of non-financial support</i>	<i>The pharmaceutical companies secure facilitation of the meetings, as well as meeting facilities and catering according to applicable regulations The companies share any expenses in this connection.</i>